Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18111697 | 0.91 | IDO1 (0.48) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112096 | 0.87 | IDO1 (0.43) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18110702 | 0.81 | IDO1 (0.42) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112002 | 0.81 | IDO1 (0.42) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18110704 | 0.81 | IDO1 (0.42) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112224 | 0.81 | IDO1 (0.41) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112225 | 0.81 | IDO1 (0.41) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112306 | 0.80 | ALDH1A1 (0.43) | MAPTIDO1KDM4ESMN1; SMN2CSF1R | |
| SCHEMBL18112081 | 0.79 | MAPT (0.37) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL18112079 | 0.79 | MAPT (0.37) | MEN1KMT2AMAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | MEN1 2981/4885KMT2A 461/4885MAPT 1988/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | MEN1 2981/4885KMT2A 461/4885MAPT 1988/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | MEN1 2234/4885KMT2A 400/4885MAPT 3241/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | MEN1 2234/4885KMT2A 400/4885MAPT 3241/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | MEN1 2234/4885KMT2A 400/4885MAPT 3241/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | MEN1 2981/4885KMT2A 461/4885MAPT 1988/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | MEN1 2234/4885KMT2A 400/4885MAPT 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.